Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000092

Drug Information
NameBicalutamide    
SynonymsCosudex; Casodex, Cosudex, Calutide, Kalumid, Bicalutamide; CPD000466329; CHEMBL409; I06-0480; Bicalutamide (JAN/USP/INN); MLS001424047; Raffolutil; CID2375; AC1L1DJE; SAM001246612; MolPort-006-808-679; SMR000466329; AstraZeneca brand of bicalutamide; ICI 176334; NCGC00167977-02; S1190_Selleck; LS-119125; NCGC00167977-01; Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,; C053541; I06-0475; KS-1161; Astra brand of bicalutamide; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide; FT-0080576; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; MLS000759437; Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-; 90357-06-5; C08160; Casodex; BRN 5364666; bicalutamide; C18H14F4N2O4S; ICI-176334; Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; DB01128; MolPort-003-845-034; D00961; NSC722665; HMS2051B13; Zeneca brand of bicalutamide; Casodex (TN); Bicalutamide [USAN:INN:BAN]; TL8005814; propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-,(+-); AC-4232; HMS2089N12    
Trade NameCasodex; Cosudex; Calutide; Kalumid    
CompanyAstraZeneca plc    
IndicationAdvanced prostatic cancerApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 90357-06-5
FormularC18H14F4N2O4S    
PubChem Compound IDCID 2375.    
PubChem Substance IDSID 10360.    
ChEBI3090;    
SuperDrug ATC IDL02BB03;    
SuperDrug CAS ID090357065;    
TargetAndrogen receptorAntagonist[2][3]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2009 Jun 17. [Epub ahead of print] To Reference
Ref 3Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543